ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have high unmet medical needs. Our clinical pipeline includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of an orphan renal disease, focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases.

Our accomplished leadership team has demonstrated success across all disciplines in the biopharmaceutical industry. A key focus is assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors.

Our evolving product pipeline is targeted to the $60+ billion anti-inflammatory market1 and the $13+ billion renal drug market2. Our lead renal drug candidate is 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), a cholesterol efflux mediator demonstrated in preclinical studies to promote cholesterol removal from podocytes, the kidney's filtering system, slowing progression of podocyte injury and renal disease. Our lead anti-inflammatory drug candidate is a novel inflammasome inhibitor targeting the upstream innate immune system. It inhibits the ASC component of inflammasomes, blocking intracellular initiation of the inflammatory cascade and extracellular perpetuation of inflammation.


  1. Credence Research, Inc. Anti-inflammatory Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018-2026
  2. Global Chronic Kidney Disease (CKD) Drugs Market to 2025. Research and Markets, September 2017